Abstract
Multiple placebo-controlled trials have demonstrated that intravenous vernakalant, a novel antiarrhythmic agent, effectively converts recent-onset atrial fibrillation in ∼50% of patients within 90 min of administration. Results from the AVRO trial corroborate these findings and further show that vernakalant is superior to amiodarone in the treatment of this condition.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.